Related Experiment Video
Updated: Feb 12, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
Yirepanjaing Ailiyaer1, Xiuxiu Wang1, Yan Zhang1
1Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, China.
Background:
Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of nebulized amikacin treatment are unknown.
Objective:
The purpose of this study was to explore the efficiency and adverse effects of nebulized amikacin treatment for 2 weeks, administered as intravenous therapy during exacerbation of BE patients infected with P. aeruginosa.
Methods:
A total of 143 patients with exacerbation of BE were screened between January 2013 and March 2016 at five tertiary hospitals in Shandong Province, China. The BE patients were diagnosed by high-resolution computed tomography scans, and all of them were confirmed to be infected with P. aeruginosa after sputum culture test. Seventy-four patients were assigned to the intervention group and received amikacin nebulization (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy. Sixty-nine patients were assigned to the control group and received standard antibiotic therapy alone. The primary outcome was the rate of bacterial eradication from the sputum, and the secondary outcomes were drug resistance and adverse effects.
Results:
The bacterial eradication rate of sputum in the intervention group (51.4%) was significantly higher compared to that in the control group (23.2%) (χ2 = 14.211, p = 0.030). Drug sensitivity testing showed that there were 5 drug-resistant cases in the intervention group and 7 in the control group, which was not significantly different. Three patients dropped out of the trial due to adverse effects. None of the patients hat renal injury.
Conclusions:
Nebulized amikacin treatment is a safe treatment for exacerbation of BE and significantly increases the bacterial eradication rate of sputum.
Insights
Nebulized amikacin effectively eradicates Pseudomonas aeruginosa in bronchiectasis patients. This safe treatment significantly improves sputum bacterial clearance during exacerbations.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a common pathogen in bronchiectasis (BE).
- The efficacy and safety of nebulized amikacin for BE exacerbations remain unclear.
Purpose of the Study:
- To evaluate the efficiency and safety of 2-week nebulized amikacin treatment for BE patients with P. aeruginosa infection during exacerbations.
Main Methods:
- 143 BE patients with P. aeruginosa exacerbations were randomized.
- Intervention group received nebulized amikacin plus intravenous antibiotics.
- Control group received standard intravenous antibiotics alone.
Main Results:
- Bacterial eradication rate was significantly higher in the amikacin group (51.4%) versus control (23.2%).
- No significant difference in drug resistance between groups.
- Adverse effects led to 3 dropouts; no renal injury observed.
Conclusions:
- Nebulized amikacin is a safe and effective treatment for P. aeruginosa exacerbations in BE patients.
- Nebulized amikacin significantly enhances sputum bacterial eradication.
Related Concept Videos
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Statistical Software for Data Analysis and Clinical Trials
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers

